Novavax's Coronavirus Vaccine Induced Antibodies in 100% of Phase 1 Trial Participants

Novavax (NASDAQ: NVAX) is trailing the leaders in the race to develop the first vaccine to protect against the novel coronavirus that causes COVID-19. In the phase 1 portion of the phase 1/2 clinical trial, two doses of NVX-CoV2373 induced neutralizing antibodies in every volunteer in the study. Neutralizing antibodies are capable of blocking infection by the coronavirus in laboratory tests and hopefully will protect patients from developing COVID-19 if they're exposed to the coronavirus, although Novavax doesn't have any data on the latter yet.